Spero Biopharma
PrivateLast Round
Debt
Jul 14, 2026
Est. Valuation
$62.55M
Total Funding Raised
$403.4M
Company Overview
Spero Biopharma operates in Healthcare & Life Sciences and is based in Israel. Its latest recorded funding round was a Debt round in July 2026.
Spero Biopharma is a biotechnology company that develops innovative pharmaceutical treatments for mild cognitive impairment and non-alcoholic steatohepatitis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Spero Biopharma Comparables
Compare Spero Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AgeneBio, Inc. | 85% | |
| Alzheon | 78% | |
| CuraSen Therapeutics, Inc. | 73% |
For institutional investors. Book with your work email.
Spero Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jul 14, 2026 | ||||
| Strategic | Sep 21, 2022 | ||||
| Private Placement | Sep 21, 2022 | ||||
| Private Placement | Jun 30, 2021 | ||||
| Follow-on Offering | Feb 11, 2020 | ||||
Private Placement | Dec 1, 2019 |
For institutional investors. Book with your work email.
Spero Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HealthCare Royalty Partners | Debt |
| RA Capital Management | Series C |
| GV | Series C |
| Lundbeckfonden BioCapital | Series C |
| Mass General Brigham Innovation | Series B, Series A |
| Osage University Partners | Series C |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2022
$9M round with ASC Oncology GmbH
- Sep 21, 2022
$66M round led by GSK plc.
For institutional investors. Book with your work email.
Spero Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Spero Biopharma's valuation, stock price, and market status.
Is Spero Biopharma a public or private company?
Spero Biopharma is a private company.
What is the current stock price of Spero Biopharma?
Spero Biopharma is a private company, so its shares have no public market price. Caplight tracks Spero Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Spero Biopharma worth (valuation)?
Spero Biopharma's valuation is estimated at $62.5M based on funding round data.
Can I buy Spero Biopharma stock?
Spero Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Spero Biopharma's last funding round?
Spero Biopharma's most recent funding round was Debt on July 14, 2026.
Who are the main investors in Spero Biopharma?
Key investors in Spero Biopharma include HealthCare Royalty Partners, GV, Lundbeckfond Ventures.
Will Spero Biopharma IPO soon?
No public IPO plans have been announced for Spero Biopharma.
How can I track Spero Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Spero Biopharma's shares on secondary markets.